Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1874 • ACR Convergence 2020
Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing Spondylitis
Mark Hwang¹, Martin Rozycki², Theresa Arndt², Esther Yi³ and Michael Weisman⁴, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Healthcare claims databases can be used to identify patients with ankylosing spondylitis (AS) prior to diagnosis. This study explores differences in pathways to AS…
Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Feyza Nur Yücel¹ and Mehmet Tuncay Duruöz², ¹Marmara University School of Medicine PMR Department, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…
Abstract Number: 0341 • ACR Convergence 2020
Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity
Wei Han¹, Xiaohang Wang¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: In this work, we applied a high-performance chemical isotope labeling (CIL) LC-MS platform to search for biomarker candidates of PsA and AS in human…
Abstract Number: 0892 • ACR Convergence 2020
Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
Sergio Schwartzman¹, David Sandoval², Andris Kronbergs², Jeffrey Lisse³, Himanshu Patel³, Wen Xu³, Soyi Liu-Leage³, Marina Magrey⁴, Helena Marzo-Ortega⁵ and Denis Poddubnyy⁶, ¹Weill Cornell Medical College, New York, NY, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in the treatment of the axial spondyloarthritis (axSpA) spectrum (ankylosing spondylitis and…
Abstract Number: 1323 • ACR Convergence 2020
Pregnancy in Axial Spondyloarthropathy: A Systematic Review & Meta-Analysis
Sinead Maguire¹, Tom O'Dwyer², Fiona Wilson³, David Mockler³ and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²Independent Researcher, Dublin, Ireland, ³Trinity College Dublin, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis affecting the sacroiliac joints and the spine. Although this chronic condition affects a wide range of ages,…
Abstract Number: 1517 • ACR Convergence 2020
Metabolic Regulation of Type 3 Innate Lymphoid Cells by Intestinal Bacteria-Derived Indoles in Ankylosing Spondylitis
Adam Berlinberg¹, Adam Lefferts², Emilie Regner³, Andrew Stahly⁴ and Kristine Kuhn⁴, ¹University of Colorado, Denver, CO, ²University of Colorado, Anschutz Medical Campus, Denver, CO, ³University of California San Francisco, San Francisco, CA, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Intestinal microbial dysbiosis, intestinal inflammation, and Th17 immunity are all linked to the pathophysiology of ankylosing spondylitis (AS); however, the mechanisms linking them remain…
Abstract Number: 1875 • ACR Convergence 2020
Heterogeneity Amongst Men and Women with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Zhixiu Li¹, Muhammad Khan², Mohammad Khan³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶, Sjef van der Linden⁷ and Matthew Brown⁸, ¹Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ²Case Western Reserve University, Cleveland OH, Westlake, OH, ³Kent State University, Kent, OH, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ⁸Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axial disease (nr-axSpA). Our purpose was to investigate genetic heterogeneity of clinically diagnosed axSpA.Methods:…
Abstract Number: 1904 • ACR Convergence 2020
Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis
Xenofon Baraliakos¹, Rebecca Bolce², David Sandoval², Soyi Liu-Leage³, Vladimir Geneus³, David Adams³, Atul Deodhar⁴, Jessica Walsh⁵ and Joachim Sieper⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Oregon Health & Science University, Portland, OR, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…
Abstract Number: 0350 • ACR Convergence 2020
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
Atul Deodhar¹, Philip Mease², Paula Machado³, Effie Pournara⁴, Xiangyi Meng³, Vibeke Strand⁵ and Marina Magrey⁶, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease involving the sacroiliac joints and spine and associated with pain, stiffness, and disability.1 A previous analysis…
Abstract Number: 0899 • ACR Convergence 2020
Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial
Denis Poddubnyy¹, Effie Pournara², Agnieszka Zielinska³, Asta Baranauskaite⁴, Alejandro Muñoz Jiménez⁵, Sanchayita Sadhu⁶, Barbara Schulz², Michael Rissler², Chiara Perella² and Helena Marzo-Ortega⁷, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Medycyna Kliniczna, Warszawa, Poland, ⁴Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁵H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ⁶Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ⁷The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early…
Abstract Number: 1326 • ACR Convergence 2020
Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study
Sali Merjanah¹, Mohamad Bittar² and Marina Magrey³, ¹Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ²The University of Tennessee Health Science Center, Memphis, TN, ³Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Increased cancer risk has been reported with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), but the correlation is poorly studied in Ankylosing spondylitis…
Abstract Number: 1521 • ACR Convergence 2020
A Novel Gut-joint Migratory TCRab+ Cell Subset Relies on sphingosine-1-phosphate for Tissue Localization
Adam Lefferts¹, Emilie Regner², Eric Norman³, David Claypool⁴, Hannah Schultz⁴, Danielle Sansone-Poe⁴ and Kristine Kuhn⁵, ¹University of Colorado, Anschutz Medical Campus, Aurora, CO, ²University of California San Francisco, San Francisco, CA, ³University of Colorado, Anschutz Medical Campus, Denver, ⁴University of Colorado, Anschutz Medical Campus, Aurora, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Despite findings of similar immune cellular phenotypes in the gut and joint of patients with spondyloarthritis, the mechanistic linkage between intestinal immunology and the…
Abstract Number: 1877 • ACR Convergence 2020
Diagnosis of Axial Spondyloarthritis: A Primary Unmet Educational Need for Rheumatologists Is Interpretation of MRI
Walter Maksymowych¹, Liron Caplan², Atul Deodhar³, Soha Dolatabadi⁴, Mark Hwang⁵, Adam Carlson⁶, Kelly Steed⁷, Amanda Carapellucci⁸, Joel Paschke⁸ and Lianne Gensler⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, ³Oregon Health & Science University, Portland, OR, ⁴Soha Dolatabadi, MD, Los Angeles, CA, ⁵McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁶University of Virginia, Charlottesville, VA, ⁷James J. Peters VA Medical Center, Bronx, NY, ⁸CARE Arthritis, Edmonton, AB, Canada, ⁹University of California San Francisco, San Francisco, CA
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging because of absent physical findings in early disease and the limited diagnostic performance of laboratory markers. Considerable…
Abstract Number: 2013 • ACR Convergence 2020
Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Sjef van der Linden¹, Peter Villiger², Zhixiu Li³, Matthew Brown⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ³Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁴Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Familial occurrence of ankylosing spondylitis (AS) is well known. Our follow-up study aimed at assessing the incidence of clinically defined AS among first degree…
Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Uta Kiltz¹, Jan Brandt-Jürgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ³Ambulantes Rheumazentrum, Erfurt, Germany, ⁴Hannover Medical School, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].